Opportunities Preloader

Please Wait.....

Report

Global Biosimilars Market Report and Forecast 2023-2031

Market Report I 2023-04-26 I 147 Pages I EMR Inc.

Global Biosimilars Market Report and Forecast 2023-2031

Global Biosimilars Market Outlook

The biosimilars market size attained a value of USD 24.5 billion in 2022. The market is likely to grow at a CAGR of 17.60% during the forecast period of 2023-2031, likely to attain a value of USD 105.1 billion by 2031.

Biosimilars Market: Introduction and Application
Biosimilars are biological products that are highly similar to an already approved and marketed reference biologic drug, with no clinically meaningful differences in terms of safety, purity, and potency. They are derived from living organisms, such as bacteria, yeast, or mammalian cells, and are used to treat various diseases and medical conditions. Biosimilars are developed after the patent expiration of the original biologic drug, also known as the innovator product.
Biosimilars are used to treat a wide range of conditions, including autoimmune disorders (examples- rheumatoid arthritis and inflammatory bowel disease), cancer, diabetes, and blood disorders (examples- anaemia and neutropenia). They are used as therapeutic proteins, monoclonal antibodies, and hormones, among other applications.
The benefits of biosimilars include the following:
- Cost Savings: As biosimilars are often less expensive than the reference biologic drugs, they can lead to substantial cost savings for healthcare systems and patients. This affordability increases patient access to essential medicines and treatments.
- Competition: The introduction of biosimilars fosters market competition, which can drive down the prices of biologic drugs and improve their availability.
- Innovation: Developing biosimilars requires extensive research and development, which can lead to the discovery of new therapeutic strategies and enhancements in biopharmaceutical manufacturing processes.
- Expanding Treatment Options: The availability of biosimilars can provide healthcare professionals and patients with additional treatment options, leading to more personalized and effective care.
Biosimilars Market Segmentations
The market can be categorised into product type, drug type, indication, procedure, and region.
Market by Product Type
- Recombinant Glycosylated Proteins
o Monoclonal Antibodies
o Erythropoietin
- Recombinant Non-Glycosylated Proteins
o Insulins
o Granulocyte Colony Stimulating Factors
o Interferons
o Others
Market Breakup by Drug Class
- Insulin
- Recombinant Human Growth Hormone (RHGH)
- Granulocyte Colony-Stimulating Factor
- Interferon
- Erythropoietin
- Etanercept
- Monoclonal Antibodies
- Follitropin
- Glucagon
- Calcitonin
- Teriparatide
- Enoxaparin Sodium
- Others
Market Breakup by Indications
- Chronic Diseases
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Blood Disorders
- Growth Hormone Deficiency
- Others
Market Breakup by Procedure
- Invasive
- Non-Invasive
Biosimilars Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others


Biosimilars Market Scenario
The global biosimilars market has been witnessing rapid growth, driven by factors such as patent expiration of blockbuster biologic drugs, increasing prevalence of chronic diseases, and rising demand for cost-effective treatment options. Regulatory support and streamlined approval pathways have facilitated the entry of biosimilars into the market, leading to increased competition and more affordable healthcare options.
In addition, the growing awareness of biosimilars among healthcare professionals and patients has further fuelled market expansion. Emerging markets, such as those in Asia Pacific and Latin America, offer significant growth potential due to their large patient populations and improving healthcare infrastructure. Key industry players are focusing on strategic partnerships, collaborations, and mergers and acquisitions to strengthen their product pipelines, expand their global presence, and capitalize on the growing market opportunities. Overall, the biosimilars market scenario presents a promising outlook, with the potential to significantly improve patient access to life-changing therapies and alleviate the financial burden on healthcare systems worldwide.
Key Players in the Global Biosimilars Market

The report gives an in-depth analysis of the key players involved in the biosimilars market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Novartis AG
- Orion Pharma
- Pfizer Inc.
- Samsung Bioepis
- Coherus BioSciences, Inc.
- Amgen Inc.
- Eli Lilly and Company.
- Takeda Pharmaceutical Company Limited.
- Bristol-Myers Squibb Company
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- Biocon
- Bayer AG
- AbbVie Inc,
- Allergan
- Dr. Reddy's Laboratories Ltd.
- Boehringer Ingelheim International GmbH.
- Biogen

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biosimilars Market Overview
3.1 Global Biosimilars Market Historical Value (2016-2022)
3.2 Global Biosimilars Market Forecast Value (2023-2031)
4 Global Biosimilars Market Landscape
4.1 Global Biosimilars Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biosimilars Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Drug Class
4.2.3 Analysis by Procedure
5 Global Biosimilars Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biosimilars Market Segmentation
6.1 Global Biosimilars Market by Product Type
6.1.1 Recombinant Glycosylated Proteins
6.1.1.1 Monoclonal Antibodies
6.1.1.2 Erythropoietin
6.1.2 Recombinant Non-Glycosylated Proteins
6.1.2.1 Insulins
6.1.2.2 Granulocyte Colony Stimulating Factors
6.1.2.3 Interferons
6.1.2.4 Others
6.2 Global Biosimilars Market by Drug Class
6.2.1 Market Overview
6.2.2 Insulin
6.2.3 Recombinant Human Growth Hormone (RHGH)
6.2.4 Granulocyte Colony-Stimulating Factor
6.2.5 Interferon
6.2.6 Erythropoietin
6.2.7 Etanercept
6.2.8 Monoclonal Antibodies
6.2.9 Follitropin
6.2.10 Glucagon
6.2.11 Calcitonin
6.2.12 Teriparatide
6.2.13 Enoxaparin Sodium
6.2.14 Others
6.3 Global Biosimilars Market by Indications
6.3.1 Market Overview
6.3.2 Chronic Diseases
6.3.3 Oncology
6.3.4 Autoimmune Diseases
6.3.5 Infectious Diseases
6.3.6 Blood Disorders
6.3.7 Growth Hormone Deficiency
6.3.8 Others
6.4 Global Biosimilars Market by Procedure
6.4.1 Market Overview
6.4.2 Invasive
6.4.3 Non-Invasive
6.5 Global Biosimilars Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Biosimilars Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Biosimilars Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Biosimilars Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Biosimilars Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Biosimilars Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Novartis AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Orion Pharma
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Pfizer Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Samsung Bioepis
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Coherus BioSciences, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Amgen Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Eli Lilly and Company.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Takeda Pharmaceutical Company Limited.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Bristol-Myers Squibb Company
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Merck KGaA
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Teva Pharmaceutical Industries Ltd.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Biocon
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Bayer AG
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 AbbVie Inc,
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Allergan
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Dr. Reddy's Laboratories Ltd.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Boehringer Ingelheim International GmbH.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 Biogen
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
18 Global Biosimilars Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE